|
|
 |
|
Viewing report
|
|
|
|
Companion Biomarkers in Drug Development
TriMark Publications, April 2009, Pages: 320
The term “companion biomarker” means that a particular diagnostic test is specifically linked to a therapeutic drug either in drug development or in the clinic. Biomarkers of disease have long played an important role in diagnostic medicine as evidenced by the intense use of specific clinical laboratory tests in the diagnosis of disease.
Biomarkers can be used in five very distinct ways in drug development:
1) companion biomarkers can be correlated with biological events during drug development in order to validate drug targets or to predict drug response; 2) biomarkers can be used as companion diagnostics in drug development to characterize patient populations in order to better understand the extent to which new drugs reach intended therapeutic targets can alter proposed therapeutic pathways and achieve successful clinical outcomes;
3) biomarkers can be used to stratify patient populations for drug response in primary prevention or disease-modification studies, particularly in specific clinical areas such as neuron degeneration and cancer;
4) clinically useful biomarkers are becoming increasingly useful to make proper therapeutic decisions regarding candidate drugs; and
5) clinically useful biomarkers are becoming increasingly required by the FDA and other outside authorities to make proper regulatory decisions regarding candidate drugs.
This report describes new biomarker technology platforms developed for the analyses of drug targets that are connected to the effectiveness of therapeutic agents in a clinical setting. The emphasis is on those companies that are actively developing and marketing new companion diagnostic tests for performing biomarker tests during drug development, as opposed to the more routine and clinically accepted companion markers that are manufactured and marketed by large diagnostic companies for routine clinical use.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
What Is the Future Role of Predictive Safety Biomarkers in Drug Development?
Biomarkers: The Future of Next-Generation Drug R&D
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Trends in the Commercialization of Biomarkers: Tests and Companies
The Landscape of Companion Diagnostics: Challenges, Opportunities, and Future Trends
Enabling Oncology Diagnostics: Predictive Biomarkers Based on Genes, Proteins, and Pathways
Cancer Biomarkers: New Tools for Transforming Cancer Management
Biomarkers and Tests for Pharma/ Biotech R&D – Companies Products and WW Market, 2006-2011
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
Cardiovascular Biomarkers: Players, Products and Prospects (Volume III)
Cancer Biomarkers: Players, Products and Prospects (Volume I)
Can Biomarkers Increase R&D Productivity?
|
|
|
|
